"How much would it be?" I naively asked the pharmacist. Enbrel is a SureClick pen; it comes in a pack of four. That would be $1,700 for one pen and $7,000 for the pack. Excuse me? Who can afford that?

The US government unveils a list of 10 medications subject to Medicare price negotiations, including Enbrel, an expensive arthritis drug. The need for government intervention to ensure fair drug ...

The vote allows the board to consider setting a maximum price for Enbrel in Colorado when it meets again next week, which would be the first time any state took that step with any prescription drug.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has ...

The drug, called Enbrel, costs insurers an average of $46,772 per patient per year, according to 2022 data from the state’s all-payer claims database. The state board evaluated two other drugs ...

Amgen set Enbrel’s list price at $1,762.34 per 50 mg dose, meaning a full year of treatment for some patients could come out to more than $90,000 before any rebates or discounts.

In February, the Colorado Prescription Drug Affordability Board ruled the arthritis drug Enbrel was unaffordable for patients in the state. The lawsuit, filed Friday by drugmaker Amgen and two of i… ...

Sandoz (OTCQX:SDZXF), which was spun out of Swiss pharma giant Novartis (NVS) (OTCPK:NVSEF) in 2023, has developed an FDA-approved biosimilar version of Enbrel called Erelzi, and its lawsuit comes ...

In 2024, Enbrel generated $3.3 billion in revenue in the US. Sandoz received US FDA approval for Erelzi in 2016, the same year the company launched the medicine in Europe.

A Colorado board voted to move forward with setting a price ceiling on the arthritis drug Enbrel on Friday, a first-in-the-nation step that raises questions about whether a single state can reduce ...

Sandoz has filed an antitrust lawsuit in the US against Amgen, challenging alleged anti-competitive practices surrounding the biologic blockbuster Enbrel (etanercept). Filed at the US District ...